Fig 1.
Representative images of immunostaining intensity of CA9 expression in patients with NSCLC.
CA9 expression was mainly expressed at cancer cells. Intensity score was determined as follows. 0, negative; 1+, weakly positive; 2+, positive; 3+, strongly positive. Bar, 100 μm.
Fig 2.
Overall survival and disease-free survival in according to CA9 expression.
Patients showing positive CA9 expression have significantly poorer survival rates for OS (p = 0.0024) than those showing negative CA9 expression rate in 338 patients with NSCLC. Patients showing positive CA9 expression have significantly poorer survival rates for DFS (p = 0.013) than those showing negative CA9 expression.
Table 1.
Relationship between expression of CA9 and clinicopathological features in 338 patients with NSCLC.
Table 2.
Univariate and multivariable analysis for 5-year overall survival of 338 patients with NSCLC.
Table 3.
Comparison of lymph node accumulation on [18F]FDG PET/CT and pathological lymph node metastasis.
Table 4.
Sensitivity and specificity of lymph nodes metastasis based on [18F]FDG PET/CT.
Table 5.
Association of CA9 expression between biopsy samples and surgical specimens.
Fig 3.
Differences in SUVmax values of primary tumors based on histological type.
SUVmax value of the primary tumor was significantly higher (p<0.001) in SCC in compared to adenocarcinoma. Adenocarcinoma patients with lymph node metastases had significantly higher SUVmax values of the primary tumor than those without lymph node metastases. In contrast, no significant difference of SUVmax value was found between SCC patients with lymph node metastases and those without lymph node metastases.